Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the ...

Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC ...

The initiation of the registration-directed ALKAZAR study enables us to explore this potential by comparing neladalkib to a front-line standard of care in a randomized, controlled clinical trial ...

The ALKAZAR trial is designed to enroll approximately 450 TKI-naïve patients with advanced ALK-positive NSCLC. Patients will be randomized 1:1 to receive neladalkib monotherapy or alectinib ...

The study will compare neladalkib to Genentech's ALK inhibitor Alecensa in patients who've had no prior systemic treatment.